Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-α in bone marrow and peripheral blood of patients with multiple myeloma

Advances in Therapy

Volumn 23, Issue 4, 2006, Pages 635-645

  Kara, Ismail Oguz ^a   Sahin, Berksoy ^a   Gunesacar, Ramazan ^a   Unsal, Cagatay ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Angiogenesis; HGF; Myeloma; TGF PDGF AB

Indexed keywords

PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; HUMAN; LABORATORY TEST; MALE; MULTIPLE MYELOMA;

ADULT; AGED; BONE MARROW; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 33751002956     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850052     Document Type: Article

References (37)

1. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85.
2. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 1989;73:1915-1924.
3. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
4. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657-1664.
5. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM 1 and CD44. Am J Hematol. 1995;50:9-14.
6. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503-508.
7. Rajikumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia (Baltimore). 1999;13:469-472.
8. Folkman J, Klagsburn M. Vascular physiology, a family of angiogenic peptides. Nature. 1987;329:671-672.
9. Schweiger L, Neufield G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature. 1987;325:257-259.
10. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629-641.
11. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239-242.
12. Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma. 1999;32:249-256.
13. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
14. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowly JJ. Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441-450.
15. Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer. 1975;36:1192-1201.
16. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
17. Galimi F, Bagnara GP, Bonsi L, et al. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol. 1994;127:1743-1754.
18. Weimar IS, Miranda N, Muller EJ, et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol. 1998;26:885-894.
19. Weimar IS, Voermans C, Bourhis JH, et al. Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia. 1998;12:1195-1203.
20. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem. 1996;271:24655-24661.
21. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer. 1999;79:451-455.
22. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
23. Morimoto A, Okamura K, Hamanaka R, et al. Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem Biophys Res Commun. 1991;179:1042-1049.
24. Rosen EM, Grant D, Kleinman H, et al. Scatter factor stimulates migration of vascular endothelium and capillary-like tube formation. Cell Motil Factors. 1991;59:76-88.
25. Morimoto A, Tada K, Nakayama Y, et al. Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells. Jpn J Cancer Res. 1994;85:53-62.
26. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 1993;90:1937-1941.
27. Rosen EM, Grant DS, Kleinman HK, et al. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol. 1993;47:227-234.
28. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54:3153-3159.
29. Santini J, Formento JL, Francoual M, et al. Characterisation, quantification, and potential clinical value of epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 1991;13:132-139.
30. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11:1873-1878.
31. Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor-α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4:13-20.
32. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332-1339.
33. Josephs SF, Ratner L, Clarke MF, Westin EH, Reitz MS, Wong-Staal F. Transforming potential of human c-sis nucleotide sequences encoding platelet-derived growth factor. Science. 1984;225:636-639.
34. Hannink M, Donoghue DJ. Structure and function of platelet-derived growth factor (PDGF) and related proteins. Biochim Biophys Acta. 1989;989:1-10.
35. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;15:203-208.
36. Mitlak BH, Finkelman RD, Hill EL, et al. The effect of systemically administered PDGF-BB on the rodent skeleton. J Bone Miner Res. 1996;11:238-247.
37. Cohen AM, Soderberg C, Thomason A. Plasma clearance and tissue distribution of recombinant human platelet-derived growth factor (B-chain homodimer) in rats. J Surg Res. 1990;49:447-452.